Skip to content

Solid Biosciences Inc. SLDB Other Noncash Income (Expense)

Other Noncash Income (Expense) at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$1.29M+394%
Taysha Gene Therapies, Inc. logo
Taysha Gene Therapies, Inc.TSHA
-$27K-640%
uniQure logo
uniQureQURE
$242K-93.9%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
-$8.8M-291%
Biogen logo
BiogenBIIB
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN

Other financials

Income statement

See full
Revenue$2.0M-40.6%
Operating income-$57.3M-43.1%
Net income-$56.7M-44.4%
EPS (diluted)-$0.52+11.9%

Balance sheet

See full
Cash & equivalents$297.1M+41.1%
Total debt$20.7M-12.5%
Total equity$374.1M+27.1%
Total assets$422.9M+23.0%

Cash flow

See full
Operating cash flow-$47.2M-48.3%
CapEx$165.0K+31.0%
Free cash flow-$47.4M-48.2%

Valuation

See full
Market cap$872.26M+135%
Enterprise value$595.83M+223%
P/S107.8×-9.9×

Profitability

See full
Operating margin-1,315.2%-4,060pp
Net margin-1,062.3%-251,151pp
FCF margin-1,247.7%-9,569pp

Returns & leverage

See full
Return on equity-57.4%+2.2pp
Debt / equity0.1×0.0×
Current ratio13.1×+2.2×

Where this comes from

Reported directly by Solid Biosciences Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherNoncashIncomeExpense.

The official record: Solid Biosciences Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Solid Biosciences Inc.'s other noncash income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Solid Biosciences Inc.'s other noncash income (expense)?
Solid Biosciences Inc. (SLDB) reported other noncash income (expense) of $0 in Q1 2026.
How has Solid Biosciences Inc.'s other noncash income (expense) changed year-over-year?
Solid Biosciences Inc.'s other noncash income (expense) decreased by 100.0% year-over-year, from $22K to $0.
What is the long-term trend for Solid Biosciences Inc.'s other noncash income (expense)?
Over 2 years (2023 to 2025), Solid Biosciences Inc.'s other noncash income (expense) has grown at a -20.1% compound annual growth rate (CAGR), from -$374K to $239K.
What does other noncash income (expense) mean?
This captures miscellaneous non-cash adjustments to net income that do not fit into standard categories like depreciation or stock-based compensation. It includes items such as changes in fair value of certain liabilities or non-cash impairment charges.